Results 71 to 80 of about 5,494 (193)
Navigating the Prescription Drug Information System
Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 855-870, October 2026.Information on new prescription drugs is increasingly complex and fragmented, posing challenges for healthcare professionals, patients, and payers. Clinicians require concise, actionable guidance to support prescribing decisions, while patients seek to balance benefits and harms when making decisions aligned with their treatment goals.
Irina V. Wang +11 more
wiley +1 more source
Journal of Neuroscience Research, Volume 104, Issue 10, October 2026.We investigated targeting Hsp72 protein expression genetically and via a drug, in a model of combined amyloid and tau pathology. Neither approach reduced amyloid or tau or improved body composition or movement ability. Both treatments tended to slightly improve survival in male mice and anxiety‐like behavior in female mice.
J. P. S. Marshall +13 more
wiley +1 more source
, 2021 Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's ...
Vivek Gupta (382944) +13 more
core
A REVIEW ON ANTIBODY OF ADUCANUMAB-REDUCES THE PROGRESSION OF ALZHEIMER DISEASE.
, 2023 Alzheimer's disease is the most common form of dementia, affecting millions of people, including family members who often act as caregivers. This devastating disease is believed to account for 8% of total US healthcare spending, with medical and nursing ...
Kolage Sakshi, Shrutika Mote, Amol Supekar, Saurabh Saudar
core +1 more source
Unveiling Aducanumab's safety profile: A comprehensive pharmacovigilance analysis.
PLoS ONEBackgroundAducanumab, a monoclonal antibody targeting amyloid-beta plaques, has been introduced as a pivotal therapeutic agent for Alzheimer's disease (AD).
Huanhuan Ji, Zongren Zhao, Chuanwei Zhao
doaj +1 more source
The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective
Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli +3 more
wiley +1 more source
Alzheimer’s Research & TherapyBackground Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) accumulation, leading to the formation of neurotoxic soluble oligomers (AβOs) that impair calcium homeostasis in neurons and astrocytes.
Lu Yu +6 more
doaj +1 more source
European Journal of Neurology, Volume 33, Issue 10, October 2026.Anti‐amyloid therapies lecanemab and donanemab are targeted at patients with early Alzheimer‐type dementia or mild cognitive impairment (MCI). In a large, Swedish multicenter memory clinic patient cohort, we found an eligibility rate of 11.5% for either treatment in the whole cohort (18.1% among dementia patients, 11.5% among aMCI patients), indicating
Anna Rosenberg +9 more
wiley +1 more source
Questions EMERGE as Biogen claims aducanumab turnaround [PDF]
, 2020 Trials of aducanumab in Alzheimer disease were previously discontinued following a phase III futility analysis, but Biogen now says that additional data indicate that longer exposure to the higher dose might be effective.
Liu, KY, Howard, R
core +1 more source
SAGE Open Medical Case Reports, 2023 A 77-year-old woman had 2 weeks of fever and flu-like symptoms starting several hours after receiving an mRNA booster for SARS-CoV-2 and the influenza vaccine, in separate shots. Laboratory tests showed cholangitis.
Linda L Restifo, Robert P Erickson
doaj +1 more source